Open Access Open Access  Restricted Access Subscription or Fee Access

Application of Prodrug to Improve Skin Permeability: A Review

Mrunal Surve, Aniruddh Belubbi, Mushtaque Shaikh, Ojaskumar Agrawal

Abstract


Administration of drug via skin has some limitations such as skin barrier, solubility of drug and partition coefficient etc. Stratum corneum which is an outer skin layer, acts as a barrier to the skin. Thus, prodrug has some applications to improve skin permeability. Prodrugs are defined as the compounds which are initially inactive but covert into their active form when reacted with several chemicals or enzymes at particular active site of body to show its desirable effect for a particular disease or condition. In skin permeability experiments, various vehicles can be used such as propylene glycol, short chain glycerides, dimethyl acetamide, cyclodextrins, N Methylpyrrolidone,azones, surfactants etc. Some mechanisms of prodrugs to improve skin permeation include, increase in partition coefficient of skin, enhanced solubilization of drug, decrease in crystal formation and modification in chemical structure of the drug. Apart from prodrug, the use of effective vehicle is of greater importance as well. As an example, for application of prodrug to improve skin permeation, two case studies have been discussed. Case study-1 includes the study of skin permeation using prodrug strategy for an opioid analgesic, Buprenorphine. In this study, the permeation of buprenorphine and its three alkyl esters across full thickness hairless mouse skin was evaluated. Thus, only acetyl buprenorphine appeared to be promising as a prodrug. In case study-2, antiviral drug acyclovir was esterified to obtain ester prodrugs of acyclovir. Hence, the five prodrugs of acyclovir showed similar skin permeability and amongst them, only acyclovir hexanoate showed 300- fold larger partition coefficient which depicts two times higher skin permeation than acyclovir. This review portrays the synthesis of prodrug to improve the skin permeability by applying enhancement mechanisms.


Keywords


Prodrugs, enzymes, cyclodextrins, surfactants, analgesic

Full Text:

PDF

References


Deepika M. An Overview on Nanoparticles. J Pharm Nanotechnol. 2015; 3(1): 9–13p.

Fang Leu. Prodrug Strategy for Enhancing Drug Delivery via Skin. Curr Drug Discov Technol. 2006; 3(3): 211–224p.

Abet V, Filace F, Recio J, Alvarez-builla J, Burgos C. Prodrug Approach : An Overview of Recent Cases. Eur J Med Chem. 2016; 127: 810–827p.

Beaumont K, Webster R, Gardner I, Dack K. Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist. Curr Drug Metab. 2003; 4(6): 461–485p.

Talluri RS, Samanta SK, Gaudana R, Mitra AK. Synthesis, Metabolism and Cellular Permeability of Enzymatically Stable Dipeptide Prodrugs of Acyclovir. Int J Pharm. 361(1–2): 118–124p.

Bragazzi NL, Sellami M, Salem I, et al. Fasting and Its Impact on Skin Anatomy, Physiology, and Physiopathology: A Comprehensive Review of the Literature. Nutrients. 2019; 11(2): 249p.

Roy N, Agrawal M, Chaudhary S, Tirkey V, Dhwaj A, Mishra N. Permeation Enhances: A Major Breakthrough in Drug Delivery Technology. Int J Pharm Sci Res. 2017; 8(3): 1001–1011p.

Li BS, Havens J, Howard C. Stratum Corneum Substantivity : Drug Development Implications. Arch Dermatol Res. 2018; 310(7): 537–549p.

Boer M, Duchnik E, Maleszka R, Marchlewicz M. Structural and Biophysical Characteristics of Human Skin in Maintaining Proper Epidermal Barrier Function. Postepy Dermatol Alergol. 2016; 33(1): 1–5p.

El Maghraby GM, Barry BW, Williams AC. Liposomes and Skin : From Drug Delivery to Model Membranes. Eur J Pharm Sci. 2008; 34(4–5): 203–222p.

Kolarsick PAJ, Kolarsick MA, Goodwin C. Anatomy and Physiology of the Skin. J Dermatol Nurses Assoc. 2008; 3(4): 203–213p.

Sciences B, Building H, Road L, Lau WM. Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement. Skin Deep: The Basics of Human Skin Structure and Drug Penetration. Springer; Nov 3, 2015; 3–11p.

N’Da DD. Prodrug Strategies for Enhancing the Percutaneous Absorption of Drugs. Molecules. 2014; 19(12): 20780–20807p.

Wong R, Geyer S, Weninger W, Guimberteau J, Wong JK. The Dynamic Anatomy and Patterning of Skin. Exp Dermatol. 2016; 25(12): 92–98p.

Tareen SHK, Kutmon M, Adriaens ME, Mariman ECM, de Kok TM, Arts ICW, Evelo CT. Exploring the Cellular Network of Metabolic Flexibility in the Adipose Tissue. Genes Nutr. 2018; 13(1): 1–8p.

Dubey S. Prodrugs : A Review. World J Pharm Res. 2018; 3(7): 277–297p.

Ghadage RV. Prodrug Design for Optimized Drug Delivery Systems. J Biol Sci Opin. 2013; 1: 255–262p.

Das N, Dhanawat M, Dash B, Nagarwal RC, Shrivastava SK. Codrug: An Efficient Approach for Drug Optimization. Eur J Pharm Sci. 2010; 41(5): 571–588p.

Kokil GR, Rewatkar PV. Bioprecursor Prodrugs : Molecular Modification of the Active Principle. Mini Rev Med Chem. 2010; 10(14): 1316–1330p.

Ceschel G, Bergamante V, Maffei P, et al. Solubility and Transdermal Permeation Properties of a Dehydroepiandrosterone Cyclodextrin Complex from Hydrophilic and Lipophilic Vehicles. Drug Deliv. 2008; 12(5): 275–280p.

Morgan CJ, Renwick AG, Friedmann PS. The Role of Stratum Corneum and Dermal Microvascular Perfusion in Penetration and Tissue Levels of Water-Soluble Drugs Investigated by Microdialysis. Br J Dermatol. 2003; 148(3): 434–443p.

Hamishehkar H, Khoshbakht M, Jouyban A, Ghanbarzadeh S. The Relationship between Solubility and Transdermal Absorption of Tadalafil. Adv Pharm Bull. 2015; 5(3): 411–417p.

Ramsden JJ. Partition Coefficients of Drugs in Bilayer Lipid Membranes. Experientia. 1993; 49: 688–692p.

Bhal S, Log P. Making Sense of the Value. Adv Chem Dev. 2007; 1–4p.

Geinoz S, Guy RH, Testa B, Carrupt PA. Quantitative Structure-Permeation Relationships (QSPeRs) to Predict Skin Permeation: A Critical Evaluation. Pharm Res. 2004; 21(1): 83–92p.

Guy RH, Hadgraft J. Transdermal Drug Delivery: A Simplified Pharmacokinetic Approach. Int J Pharm. 1985; 24(2–3): 267–274p.

Effect of Ionization and Vehicle on Skin Absorption and Penetration of Azelaic Acid. Drug Dev Ind Pharm. 2012; 38(8): 985–994p.

Po HN, Senozan NM. The Henderson-Hasselbalch Equation: Its History and Limitations. J Chem Educ. 2001; 78(11): 1499–1503p.

Alkilani AZ, Mccrudden MTC, Donnelly RF. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the Stratum Corneum. Pharmaceutics. 2015; 7(4): 438–470p.

Uchida T, Kadhum WR, Kanai S, Todo H, Oshizaka T, Sugibayashi K. Prediction of Skin Permeation by Chemical Compounds Using the Artificial Membrane, Strat-MTM. Eur J Pharm Sci. 2015; 67(C): 113–118p.

Majumdar S, Sloan KB. Enhancing Topical Delivery Using Prodrugs. Pharm Technol Eur. 2007; 19: 33–35p.

Arnott JA, Planey SL. The Influence of Lipophilicity in Drug Discovery and Design. Expert Opin Drug Discov. 2012; 7(10): 863–75p.

Magnusson BM, Anissimov YG, Cross SE, Roberts MS. Molecular Size as the Main Determinant of Solute Maximum Flux Across the Skin. J Invest Dermatol. 2004; 122(4): 993–999p.

Bos JD, Meinardi MMHM. The 500 Dalton Rule for the Skin Penetration of Chemical Compounds and Drugs. Exp Dermatol. 2000; 9(3): 165–169p.

Walicka A, Iwanowska-Chomiak B. Drug Diffusion Transport Through Human Skin. Int J Appl Mech Eng. 2018; 23(4): 977–988p.

Franc I, Lipinski A, Feeney PJ. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv Drug Deliv Rev. 2001; 46(1–3): 3–26p.

Todo H. Transdermal Permeation of Drugs in Various Animal Species. Pharmaceutics. 2017; 9(3): 33p.

Karpanen TJ, Worthington T, et al. Penetration of Chlorhexidine into Human Skin Penetration of Chlorhexidine into Human Skin. Antimicrob Agents Chemother. 2008; 52(10): 3633–6p.

Franz TJ, Lehman PA, Raney SG. Use of Excised Human Skin to Assess the Bioequivalence of Topical Products. Skin Pharmacol Physiol. 2009; 22(5): 276–286p.

Abd E, Yousef SA, Pastore MN, et al. Skin Models for the Testing of Transdermal Drugs. Clin Pharmacol Adv Appl. 2016; 8: 163–176p.

Sugibayashi K, Todo H, Oshizaka T, Owada Y. Mathematical Model to Predict Skin Concentration of Drugs : Toward Utilization of Silicone Membrane to Predict Skin Concentration of Drugs as an Animal Testing Alternative. Pharm Res. 2010; 27(1): 134–142p.

Takeuchi H, Mano Y, Terasaka S, Sakurai T, Furuya A, Urano H, Sugibayashi K. Usefulness of Rat Skin as a Substitute for Human Skin in the in Vitro Skin Permeation Study. Exp Anim. 2011; 60(4): 373–384p.

Todo H, Oshizaka T, Kadhum WR, Sugibayashi K. Mathematical Model to Predict Skin Concentration after Topical Application of Drugs. Pharmaceutics. 2013; 5(4): 634–651p.

Uchida T, Yakumaru M, Nishioka K, Higashi Y, Sano T, Todo H, Sugibayashi K. Evaluation of a Silicone Membrane as an Alternative to Human Skin for Determining Skin Permeation Parameters of Chemical Compounds. Chem Pharm Bull. 2016; 64(19): 1338–1346p.

Alvarez-Figueroa MJ, Pessoa-Mahana CD, et al. Evaluation of the Membrane Permeability (PAMPA and Skin) of Benzimidazoles with Potential Cannabinoid Activity and their Relation with the Biopharmaceutics Classification System (BCS). AAPS Pharm Sci Tech. 2011; 12(2): 573–8p.

Sinkó B, Vizserálek G, Novák KT. Skin PAMPA : Application in Practice. ADMET & DMPK. 2015; 2(4): 191–198p.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Research & Reviews: A Journal of Drug Formulation, Development and Production